Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday?

All NewsJune 30, 2025

Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent